TY - JOUR
T1 - S5733 Under Pressure
T2 - 2025 ACG Annual Meeting Abstracts
AU - Fernandez, Emilio
AU - Dominguez Rivera, Grecia
AU - Tsai, Eugenia
AU - Pedicone, Lisa D.
AU - Gomez-Aldana, Andres
AU - Landaverde, Carmen
AU - Petrasek, Jan
AU - Lawitz, Eric
AU - Poordad, Fred
AU - Rodas, Fabian
N1 - Publisher Copyright:
© 2025 by The American College of Gastroenterology
PY - 2025/10
Y1 - 2025/10
N2 - Introduction: Mycobacterium avium complex (MAC), an environmental pathogen acquired via inhalation or ingestion, frequently causes disseminated disease in immunocompromised patients, notably those with AIDS. Hepatic involvement occurs in over 50% of disseminated cases, often manifesting as granulomatous liver disease. We present a case of a patient who developed transaminitis and new-onset ascites in the setting of granulomatous liver disease secondary to disseminated MAC. Case Description/Methods: A 27-year-old man with a past medical history of AIDS and disseminated MAC was directly admitted due to chronic diarrhea and MAC bacteremia. The patient was initially diagnosed with disseminated MAC in February 2024 and closely followed by Infectious Diseases with outpatient antibiotic management (rifabutin, ethambutol, and azithromycin). In late December 2024, the patient was admitted for esophageal candidiasis. Blood cultures at that time were positive for MAC with new resistances. The patient was admitted and began treatment with intravenous (IV) amikacin. During admission, the patient developed elevated liver-associated enzymes, aspartate aminotransferase (AST) 160 U/L, alanine aminotransferase (ALT) 142 U/L, and alkaline phosphatase (ALP) 518 U/L with new-onset ascites. A computed tomography liver 4 phase was only significant for mild hepatomegaly. Paracentesis was performed with studies showing a serum-ascites albumin gradient of 1.3. An IR-guided transjugular liver biopsy was consistent with portal hypertension (portal gradient = 22 mm Hg). Histology showed hepatic parenchyma with multiple non-necrotizing poorly formed granulomatous containing acid-fast bacilli, consistent with MAC. The patient was discharged on ethambutol, rifabutin, azithromycin, and IV amikacin. At a recent follow-up, the patient reports resolution of diarrhea, though he has still required 3 paracenteses in the 3 months following discharge. His liver-associated enzymes have since down trended and are now near or within normal limits: AST 19 U/L, ALT 16 U/L and ALP 179 U/L. Discussion: Hepatic granulomas are observed in 2% to 10% of all liver biopsy specimens and are a hallmark of disseminated Mycobacterium avium complex infection, particularly in immunocompromised patients. Non-cirrhotic portal hypertension, as seen in this case, is a rare complication of granulomatous liver disease. Clinically, patients may present with ascites and other sequelae of portal hypertension. Pathophysiology involves granulomatous inflammation compressing intrahepatic venous lumina, coupled with fibrosis from resolving granulomas, which leads to elevated portal pressures.
AB - Introduction: Mycobacterium avium complex (MAC), an environmental pathogen acquired via inhalation or ingestion, frequently causes disseminated disease in immunocompromised patients, notably those with AIDS. Hepatic involvement occurs in over 50% of disseminated cases, often manifesting as granulomatous liver disease. We present a case of a patient who developed transaminitis and new-onset ascites in the setting of granulomatous liver disease secondary to disseminated MAC. Case Description/Methods: A 27-year-old man with a past medical history of AIDS and disseminated MAC was directly admitted due to chronic diarrhea and MAC bacteremia. The patient was initially diagnosed with disseminated MAC in February 2024 and closely followed by Infectious Diseases with outpatient antibiotic management (rifabutin, ethambutol, and azithromycin). In late December 2024, the patient was admitted for esophageal candidiasis. Blood cultures at that time were positive for MAC with new resistances. The patient was admitted and began treatment with intravenous (IV) amikacin. During admission, the patient developed elevated liver-associated enzymes, aspartate aminotransferase (AST) 160 U/L, alanine aminotransferase (ALT) 142 U/L, and alkaline phosphatase (ALP) 518 U/L with new-onset ascites. A computed tomography liver 4 phase was only significant for mild hepatomegaly. Paracentesis was performed with studies showing a serum-ascites albumin gradient of 1.3. An IR-guided transjugular liver biopsy was consistent with portal hypertension (portal gradient = 22 mm Hg). Histology showed hepatic parenchyma with multiple non-necrotizing poorly formed granulomatous containing acid-fast bacilli, consistent with MAC. The patient was discharged on ethambutol, rifabutin, azithromycin, and IV amikacin. At a recent follow-up, the patient reports resolution of diarrhea, though he has still required 3 paracenteses in the 3 months following discharge. His liver-associated enzymes have since down trended and are now near or within normal limits: AST 19 U/L, ALT 16 U/L and ALP 179 U/L. Discussion: Hepatic granulomas are observed in 2% to 10% of all liver biopsy specimens and are a hallmark of disseminated Mycobacterium avium complex infection, particularly in immunocompromised patients. Non-cirrhotic portal hypertension, as seen in this case, is a rare complication of granulomatous liver disease. Clinically, patients may present with ascites and other sequelae of portal hypertension. Pathophysiology involves granulomatous inflammation compressing intrahepatic venous lumina, coupled with fibrosis from resolving granulomas, which leads to elevated portal pressures.
UR - https://www.scopus.com/pages/publications/105025966176
UR - https://www.scopus.com/pages/publications/105025966176#tab=citedBy
U2 - 10.14309/01.ajg.0001150392.48620.ad
DO - 10.14309/01.ajg.0001150392.48620.ad
M3 - Conference article
AN - SCOPUS:105025966176
SN - 0002-9270
VL - 120
SP - S23-S23
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 10S2
Y2 - 24 October 2025 through 29 October 2025
ER -